Illumina Inc. Stock (US4523271090): Analyst Ratings and Price Targets in Focus

Illumina Inc. (ILMN) has attracted renewed attention from Wall Street analysts, with a cluster of updated ratings and price targets issued over the past several months. According to a compilation of 19 Wall Street analysts, the average 12?month price target for Illumina stock stands at approximately $111.95, which represents an upside of about 16.7% from a recent reference price near $95.91, as reported by TipRanks on May 8, 2026. The range of individual targets spans from a low of roughly $75 to a high of about $185, underscoring a broad divergence in how different institutions view the company’s valuation and growth trajectory.

Among the more recent actions, Citi maintained a Sell rating on Illumina with a price target of $80, implying a downside of roughly 16.6% from the same reference level. In contrast, Guggenheim reiterated a Buy rating with a target of $114, suggesting an upside of about 18.9%. Canaccord Genuity, meanwhile, reiterated a Hold rating and raised its target from $99 to $105, pointing to a potential gain of around 9.5%. These moves reflect a cautious but not uniformly bearish stance, with several firms acknowledging Illumina’s position in the genomics market while weighing competitive pressures and margin dynamics.

As of early May 2026, Illumina’s stock trades on the NASDAQ under the ticker ILMN, with recent intraday quotes around the mid?$130s per share, according to broker?platform data. Over the past 12 months, the share price has fluctuated between roughly $74 and $158, reflecting volatility tied to earnings releases, regulatory developments, and broader market sentiment toward growth?oriented healthcare technology names. The current analyst?derived upside of about 16.7% is based on a consensus that incorporates expectations for mid?single?digit revenue growth, gradual margin expansion, and a normalized valuation multiple in the low?20s.

From a business?model perspective, Illumina generates the majority of its revenue from sequencing instruments, consumables, and associated services used in research, clinical, and applied markets. The company’s NovaSeq X platform has been a key driver of recent growth, particularly in clinical sequencing applications such as oncology, rare disease, and prenatal testing. According to a third?party analysis published in early 2026, clinical sequencing now accounts for more than two?thirds of Illumina’s sequencing consumables revenue, highlighting a strategic shift toward higher?value, regulated applications that can support more stable recurring revenue streams.

Financially, Illumina reported modest year?over?year revenue growth of about 4.8% in the first quarter of 2026, slightly ahead of consensus estimates. This performance reflects continued adoption of the NovaSeq X platform, partially offset by softer demand in certain research segments and ongoing competitive dynamics in the sequencing hardware market. The same analysis projects that Illumina could achieve around 5% annual revenue growth over the medium term, with operating margins expanding toward the mid?20% range as the research market stabilizes and the company leverages its installed base of instruments.

Valuation?wise, the third?party model cited above assumes a normalized price?to?earnings multiple of about 23.4x, which is broadly in line with historical levels for the stock when growth and margins are viewed as stable. Under these assumptions, the model suggests that Illumina’s share price could rise from a level near $127 to about $155 by the end of 2028, implying an annualized total return of roughly 7.8% over a 2.7?year horizon. This scenario hinges on sustained clinical adoption, disciplined cost management, and the absence of major regulatory or competitive setbacks.

For US investors, Illumina’s listing on the NASDAQ and its reporting in US dollars make it directly accessible to retail and institutional portfolios. The company files its financial statements with the US Securities and Exchange Commission, providing transparency on revenue by geography and end market. A portion of Illumina’s revenue is derived from customers in the United States, Europe, and Asia?Pacific, which introduces foreign?exchange risk for investors holding the stock in non?USD currencies. However, the core business model remains anchored in the US?centric life?sciences and healthcare ecosystem, where demand for genomic data continues to expand.

From a risk perspective, Illumina faces several key challenges. These include intense competition from other sequencing platform providers, potential pricing pressure in consumables, and the need to maintain high levels of innovation to protect its installed base. Regulatory scrutiny in certain jurisdictions, particularly around data privacy and the use of genetic information, could also affect the pace of clinical adoption. Additionally, any material deviation from the projected 5% revenue growth or margin trajectory would likely lead to downward revisions in analyst price targets and increased stock volatility.

Looking ahead, investors will likely focus on upcoming quarterly earnings releases, updates on NovaSeq X adoption, and any changes in analyst sentiment or guidance. The next earnings date, if confirmed by the company’s investor relations calendar, will provide an opportunity to assess whether recent growth and margin trends are on track with the assumptions embedded in current price targets. Over the medium term, the balance between clinical sequencing growth and research?market cyclicality will be a critical determinant of whether Illumina can deliver the mid?single?digit annual returns implied by current valuation models.

In summary, Illumina Inc. remains a central player in the genomics and sequencing space, with a diversified revenue base anchored in instruments and consumables. Recent analyst coverage reflects a mixed but generally constructive view, with an average 12?month target implying moderate upside from current levels. For investors, the stock offers exposure to long?term growth in clinical genomics, albeit with risks related to competition, regulation, and execution. As always, the decision to hold or trade Illumina shares should be based on individual risk tolerance, time horizon, and a thorough review of the company’s latest disclosures and market conditions.